Table 47. Patient characteristics–perphenazine versus risperidone

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Ascher-Svanum et al. 2008**131 | ***Study design:*** RCT***Registration #:*** NR***Study population:*** Schizophrenia***DSM Classification:*** DSM IV***Study period:*** May–98 to Sep–02***Number of centers:*** Multicenter(n = 21)***Setting:*** Mixed***Country:*** USA***Financial support:*** Multiple sources (NR)***Washout period performed:*** NA***Run-in phase performed:*** no***Followup period:*** 12 mo | ***Main inclusion criteria:*** aged >18 years; DSM–IV criteria for Sz, schizoaffective or schizophreniform disorders based on the SCID; minimum score of 18 on BPRS***Main exclusion criteria:*** serious or unstable physical illnesses; high risk of suicide; lactating or pregnant women and individuals with medical conditions contraindicating use of any study medication | ***G1:******Age (mean±SD):*** 44.20±11.90***Males (n(%)):*** 28/48 (58.3%)***Ethnicity:*** Caucasian 27/48(52.3%)***BL symptom scores:*** BPRS (mean±SD): 28.9±31.90PANSS (mean±SD): 81.0±18.9***G2:******Age (mean±SD):*** 42.00±11.80***Males (n(%)):*** 130/217 (60.0%)***Ethnicity:*** Caucasian 118/217 (54.3%)***BL symptom scores:*** BPRS (mean±SD): 32.4±12.20PANSS (mean±SD): 87.40±20.70 | ***G1:******Classification:*** FGA***Drug:*** Perphenazine***Dosage:*** NR***Intervals:*** NR***G2:******Classification:*** SGA***Drug:*** Olanzapine***Dosage:*** NR***Intervals:*** NR |

**Table 47. Patient characteristics–perphenazine versus risperidone (continued)**

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Lieberman et al. 2005**23  | ***Study design:*** RCT***Registration #:*** NR***Study population:*** Schizophrenia***DSM Classification:*** DSM IV***Study period:*** Jan–01 to Dec–04***Number of centers:*** Multicenter(n = 57)***Setting:*** Outpatient***Country:*** USA***Financial support:*** Multiple sources (AstraZeneca, Bristol–Myers Squibb, Forest, Janssen, Eli Lilly, Otsuka, Pfizer, Zenith Goldline, Schering–Plough, and Novartis)***Washout period performed:*** NA***Run-in phase performed:*** no***Followup period:*** 18 mo | ***Main inclusion criteria:*** Age 18–65 yrs; Dx of Sz; able to take oral AP medication***Main exclusion criteria:*** Schizoaffective disorder, mental retardation, other cognitive disorders; Hx of serious adverse reactions to study drugs; had only one schizophrenic episode; Hx of treatment resistance; pregnant or breast feeding; other serious and unstable medical condition.  | ***G1:******Age (mean±SD):*** 40.00±11.10 ***Males (n(%)):*** 199/261 (76.3%)***Ethnicity:*** Caucasian 152/261 (58.2%)***BL symptom scores:*** PANSS (mean±SD): 74.3±18.1***G2:******Age (mean±SD):*** 40.80±10.80 ***Males (n(%)):*** 244/336 (72.6%)***Ethnicity:*** Caucasian 196/336 (58.3%)***BL symptom scores:*** PANSS (mean±SD): 76.1±18.2***G3:******Age (mean±SD):*** 40.90±11.20 ***Males (n(%)):*** 255/337 (75.7%)***Ethnicity:*** Caucasian 213/337 (63.2%)***BL symptom scores:*** PANSS (mean±SD): 75.7±16.9***G4:******Age (mean±SD):*** 40.60±11.30***Males (n(%)):*** 253/341 (74.2%)***Ethnicity:*** Caucasian 204/301 (59.8%)***BL symptom scores:*** PANSS (mean±SD): 76.4±16.6***G5:******Age (mean±SD):*** 40.10±11.00***Males (n(%)):*** 129/185 (69.7%)***Ethnicity:*** Caucasian 109/185 (58.9%)***BL symptom scores:*** PANSS (mean±SD): 75.4±18.6 | ***G1:******Classification:*** FGA***Drug:*** Perphenazine***Dosage:*** 8–32mg/d***Intervals:*** once daily***G2:******Classification:*** SGA***Drug:*** Olanzapine***Dosage:*** 7.5–30mg/d***Intervals:*** once daily***G3:******Classification:*** SGA***Drug:*** Quetiapine***Dosage:*** 200–800mg/d***Intervals:*** BID***G4:******Classification:*** SGA***Drug:*** Risperidone***Dosage:*** 1.5–6.0mg/d***Intervals:*** once daily***G5:******Classification:*** SGA***Drug:*** Ziprasidone***Dosage:*** 40–160mg/d***Intervals:*** BID  |

AP = antipsychotic; BID  = Twice daily; BL = baseline; BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impressions; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; DX = diagnosis; FGA = first-generation antipsychotic; Hx = history; mg = milligram; n = number; NA = not applicable; NR = not reported; PANSS  = Positive and Negative Syndrome Scale; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; wk = week; yr = year